| TUPEB21 | CMV-Specific IgG changes during severe COVID-19 suggestive of acute reactivation | Poster exhibition | SARS-CoV-2, COVID-19 and HIV |
| TUPEB20 | HIV viral suppression and drug resistance patterns among adults and children in the era of dolutegravir use: Findings from the national representative cross-sectional survey in Tanzania | Poster exhibition | ART resistance |
| TUPEB19 | Doravirine Resistance Patterns Identified through week 192 in the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 clinical trials | Poster exhibition | ART resistance |
| TUPEB18 | Resistance to second generation integrase inhibitors after two years of a national rollout strategy in Mexico | Poster exhibition | ART resistance |
| TUPEB17 | A biodegradable, subcutaneous implant delivery platform to treat HIV for up to 6 months in young children | Poster exhibition | Other strategies and therapies |
| TUPEB16 | Transformation of 3 current short-acting HIV drugs, tenofovir, lamivudine and dolutegravir (TLD) into a novel, all-in-one long-acting TLD 3-drug-combination in a single injectable dosage that produces extended pharmacokinetics | Poster exhibition | Other strategies and therapies |
| TUPEB15 | Ruxolitinib-mediated HIV-1 reservoir decay in A5336 phase 2a trial | Poster exhibition | Other strategies and therapies |
| TUPEB14 | Recommendations for missed oral lenacapavir loading doses using population-pharmacokinetics-based simulations | Poster exhibition | Antiretroviral therapies and clinical issues in adults |
| TUPEB13 | Use of second-generation INSTIs in the treatment of children and adolescents in Mexico. A real-life national experience | Poster exhibition | Antiretroviral therapies and clinical issues in infants, children and adolescents |
| TUPEB12 | Increased dolutegravir coverage is associated with increase in viral load coverage and suppression among children living with HIV in Togo | Poster exhibition | Antiretroviral therapies and clinical issues in infants, children and adolescents |